by
Gus Iversen, Editor in Chief | October 17, 2025
Radioisotope manufacturer Nusano has signed a multi-isotope supply agreement with Ariceum Therapeutics to support the development of targeted radiopharmaceuticals, including Ariceum’s lead clinical program in small cell lung cancer and Merkel cell carcinoma.
Under the agreement, Ariceum will receive actinium-225 (Ac-225) and lutetium-177 (Lu-177) produced by Nusano to support its research and clinical programs. The Berlin-based company is currently evaluating its Ac-225–labeled radiotherapeutic, SSO110, in a Phase 1/2 trial for patients with extensive-stage small cell lung cancer and Merkel cell carcinoma.
“Radiotherapeutics have the potential to redefine the standard of care in oncology,” said Manuel Sturzbecher-Höhne, chief technology officer at Ariceum. “This agreement further strengthens our ability to advance 225Ac-SSO110. ... Reliable access to actinium-225 ensures we can deliver on our commitment to developing transformative therapies for patients facing these aggressive and underserved cancers.”
Ad Statistics
Times Displayed: 357
Times Visited: 1 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
Nusano, headquartered in West Valley City, Utah, has developed a proprietary particle acceleration platform aimed at improving isotope production capacity and reliability. The company says its technology allows for the simultaneous production of up to 12 different radioisotopes, positioning it to serve both early-stage developers and commercial suppliers.
“Nusano’s production capabilities are designed to stabilize supply chains and enable innovation,” said Chris Lowe, CEO of Nusano. “Our scalable production allows us to work with drug developers from the earliest stages through commercial drug availability.”
Ariceum’s broader pipeline also includes ATT001, a radiolabeled I-123 PARP inhibitor targeting solid tumors. The company operates internationally, with active sites across Europe, the U.S., and Australia.
Nusano continues to position itself as a domestic alternative to international radioisotope suppliers, aiming to support pharmaceutical innovation and reduce foreign dependency in isotope sourcing.
